Emine Tugba ALATAS, Suzan Demir PEKTAS, Gursoy DOGAN, Mehmet Fatih AZİK

Skin, hair and nail findings in children with beta-thalassemia

Beta thalassemia is a disease that affects many organs and leads to mortality and morbidity. We also aimed to investigate the skin findings in children with beta-thalassemia major. Between April 2016 and September 2016, cross-sectionally 24 children with beta-thalassemia who were followed-up and transfused with blood at the Thalassemia Center of Muğla Sıtkı Koçman University were included in the study. The dermatological examinations of the patients were performed by two dermatologists. In addition to dermatological examinations, additional diseases, iron chelator agents and other treatments, hemoglobin, hematocrit, ferritin levels, accompanying skin, hair and nail findings were recorded. Seventeen of the 24 beta-thalassemia patients were male (70.8%), seven were female (29.2%) evaluated in our study. When we assessed the skin, hair and nail findings of patients; 62.5% of the patients had xerosis, 54.2% had pigmentation disorders, 33.3% had nevi, 33.3% had splenectomy scar, 25% had dermatoses, 16.7% nail involvement, 16.7% had pruritus, tinea versicolor in 8.3% and other skin findings in 37.5%. As a result, xerosis was detected as the most common skin finding in our study. The second most common disorders were pigmentation diseases. Ferritin levels were found to be significantly increased in patients with impaired pigmentation. Patients with thalassemia disease should be followed for xerosis and pigmentation diseases. Moisturizing creams and sunscreens should be recommended to patients by hematology and dermatology doctors. Our study is limited with few cases, and multi-centered studies are needed in the future.

PDF

___

1. Moukalled NM, Bou-Fakhredin R, Taher AT. Deferasirox: Over a Decade of Experience in Thalassemia. Mediterr J Hematol Infect Dis. 2018;10:e2018066.

2. McGann PT, Nero AC, Ware RE. Clinical Features of β-Thalassemia and Sickle Cell Disease. Adv Exp Med Biol. 2017;1013:1-26.

3. Porter JB. Optimizing iron chelation strategies in beta-thalassemia major. Blood Rev. 2009;23Suppl:3-7.

4. Ohshita A, Nakai N, Katoh N, et al. A maculopapular type eruption associated with deferasirox administration. J Am Acad Dermatol. 2013;69:e265-7.

5. Fahmey SS, Taha G, El-Refaey A, et al. Skin Disorders in Egyptian Children with β-Thalassemia Major. J Trop Pediatr. 2018;64:104-9.

6. Dogramaci AC, Savas N, Ozer B, et al. Skin diseases in patients with beta-thalassemia major. Int J Dermatol. 2009;48:1057-61.

7. Pektas SD, Alatas ET, Pektas G, et al. Analysis of Skin, Hair and Nail Diseases in the Adults with Beta Thalassemia Major. GMJ 2018;29:128-33.

8. Noureldine MHA, Taher AT, Haydar AA, et al. Rheumatological complications of beta-thalassemia: an overview. Rheumatology (Oxford). 2018;57:19-27.

9. Giordano G, Ricci R, Froio E, et al. A case of colloid milium in a patient with beta-thalassemia major. J Cutan Pathol. 2008;35:566–9.

10. Vlachos C, Pliakou X, Gaitanis G, et al. Higher Serum Ferritin Levels Correlate with an Increased Risk of Cutaneous Morbidity in Adult Patients with β-Thalassemia: A Single-Center Retrospective Study. Acta Haematol. 2016;135:124-30.

11. Borgnapignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: Greer PJ, Foerster J, Lukens NJ, editors. Wintrobe’s Clinical Hematology, 11th Ed. Philadelphia: PA: Lippincott Williams &Wilkins; 2004:1319.

12. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of b-thalassemia majör in North America. Blood. 2004;104:34–9.

13. Farage MA, Miller KW, Berardesca E, et al. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol. 2009;10:73-86.

14. Polat AK, Belli AA, Karakus V, et al. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol. 2017;92:59-61.